HCPLive Network

Patient-Doctor Communication Affects Cardiometabolic Medication Adherence

 
FRIDAY, Jan. 4 (HealthDay News) -- Poor communication between patients and health care providers is linked to lower cardiometabolic medication adherence, according to a study published online Dec. 31 in JAMA Internal Medicine.

Neda Ratanawongsa, M.D., M.P.H., from the University of California in San Francisco, and colleagues analyzed data from 9,377 patients in the Diabetes Study of Northern California, a race-stratified, random sample of Kaiser Permanente survey respondents. In the 12 months preceding the survey, the patients received one or more oral hypoglycemic, lipid-lowering, or antihypertensive medication. Communication with their health care provider was measured with the Consumer Assessment of Healthcare Providers and Systems Survey (CAHPS) score and four items from the Trust in Physicians and Interpersonal Processes of Care instruments. Greater than a 20 percent continuous medication gap for ongoing medication therapies was used to define poor adherence.

The researchers found that 30 percent of participants had poor cardiometabolic medication refill adherence. The adjusted prevalence of poor adherence increased by 0.9 percent (P = 0.01) for each 10-point decrease in CAHPS score. Patients who gave health care providers lower ratings for involving patients in decisions, understanding patients' problems with treatment, and eliciting confidence and trust were more likely to have poor adherence, compared with patients giving higher ratings to their physicians. Hypoglycemic medications had higher associations between communication and adherence than did other medications.

"Poor communication ratings were independently associated with objectively measured inadequate cardiometabolic medication refill adherence, particularly for oral hypoglycemic medications," the authors write.
 

Abstract
Full Text (subscription or payment may be required)

 
Copyright © 2013 HealthDay. All rights reserved.
 

Further Reading
The FDA has approved Baxter’s Rixubis [Coagulation Factor IX (Recombinant)], an intravenous prophylactic treatment intended to control and prevent bleeding episodes and assist with perioperative management for children 12 years and younger with hemophilia B.
A compound known as P7C3-S243 appears to keep axons from degenerating after a blast injury, a University of Iowa mouse study has found. “We propose that P7C3-S243 serves as a chemical scaffold upon which new drugs can be designed to treat patients with condition of axonal degradation such as occurs in traumatic brain injury or other neurodegenerative disease,” the researchers wrote
Nancy Chiaravalloti, PhD, shares how cognitive function impacts patients with progressive multiple sclerosis at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston.
A new set of guidelines from the American College of Physicians (ACP) advises physicians to prescribe exercises and behavioral therapy—not drugs—as first-line treatment for many patients with urinary incontinence (UI).
Using an experimental and highly sensitive test for cardiac troponin, a team of Johns Hopkins researchers found undetected signs of heart muscle damage in people with diabetes and pre-diabetes. That may suggest that hypoglycemia directly damages the heart.
As reported in the EMBO Molecular Medicine journal, researchers have discovered there are several types of dendritic cells within human skin that play a role in both the earlier and more advances stages of psoriasis.
From 2007 to 2011, there were nearly 10,000 emergency hospitalizations per year for unsupervised prescription medication ingestion by young children, according to a study published online Sept. 15 in Pediatrics.
More Reading